Jump to section
Case study highlights
In this case study, a translational research team analysed Phase II multi-omics clinical trial data to identify candidate biomarker signals associated with patient response.
By integrating clinical outcomes with molecular and public reference data, the team distinguished responders from non-responders and generated evidence to help inform a data-driven patient-enrichment strategy ahead of later-stage development.
62% Reduction
Data Integration Time
Using AI-powered ETL and Sonrai's ability to harmonise diverse data modalities across omics and clinical records.
52% Faster
Biomarker Discovery
Sonrai's AI-supported technology accelerated candidate identification, with faster data analysis across the workflow through a code-optional environment.
32% Lower
Computational Expenditure
Via Sonrai's cloud-based platform, reducing hardware and maintenance overhead.
The client's identity has been anonymised. The programme details and reported outcomes reflect the engagement.
Screenshots shown illustrate the Sonrai Discovery platform generally and are not depictions of this client's specific data views.
From data exploration to imaging analysis and scalable pipelines, Sonrai Discovery brings Insights, Imaging and Pipelines together in a single, connected workflow for translational research.
Explore Sonrai DiscoveryThe client
A biotechnology company at the forefront of precision medicine, working to advance therapeutic success through targeted interventions and personalised treatments. This biotech venture focuses on accelerating drug discovery and development using data-driven insights, and sought to identify candidate biomarkers associated with drug response.
"With Sonrai, our skills gap became irrelevant. Their integrated approach surfaced insights into treatment response we couldn't reach on our own, giving us confidence in the biomarkers worth taking forward."
The challenge
The client aimed to uncover candidate biomarkers linked to drug response, in order to optimise patient outcomes.
- Skills and expertise gap. As an emerging player, the company had a shortage of skilled data scientists, limiting its ability to navigate complex big-data analysis and bioinformatics.
- Escaping manual constraints. Manual processes couldn't meet the speed and depth of discovery needed to achieve the precision the team was after.
- Simplifying complexity. The team wanted to harness machine learning without requiring extensive coding skills, to make its power usable across the wider team.
Do these challenges sound familiar?
If you need advice on the challenges you're facing, our team is ready to help.
Sonrai's strategy
Through the partnership, Sonrai equipped the client with an analytical approach for evaluating candidate biomarkers linked to treatment response.
- Integrated insights. Fusing clinical and molecular data modalities surfaced insights the team couldn't see when the data stayed siloed.
- Unlocking public data. The Sonrai team integrated relevant public data sources, widening the analytical context and the scope of potential findings.
- Simplified power of ML. Sonrai Discovery combines analytical capability with hands-on support from data scientists and bioinformaticians, letting the translational team apply robust analytics without needing custom code or a dedicated data-science function.
"In a competitive landscape, the team at Sonrai and their technology gave us a strategic edge. The insights we gained from this analysis strengthened our confidence in the path forward for our clinical programme."
Results
The collaboration didn't just address the client's immediate challenges — it laid the foundation for a more efficient biomarker discovery process going forward.
- 62% reduction in data integration time — using AI-powered ETL and Sonrai's ability to harmonise diverse data modalities (omics data and clinical records).
- 52% faster biomarker discovery — supported by Sonrai's AI-driven technology for candidate identification, with faster data analysis throughout the workflow via a code-optional environment usable by both technical and non-technical users.
- 32% lower computational expenditure — via Sonrai's cloud-based platform, reducing hardware and maintenance overhead.
- Supported privacy and regulatory requirements — through data validation, traceability and role-based access controls.
- Supported more efficient trial preparation — streamlined integration and analysis reduced manual friction ahead of later-stage development.
- Reduced reliance on external consultancy — Sonrai Discovery let the in-house team conduct advanced analysis without depending heavily on outside expertise.
- Broader analytical context — relevant public reference data was integrated alongside internal sources to widen the evidence available.
Get in touch to discuss the full case study.
Discovering biomarker potential
The partnership produced a shortlist of candidate biomarkers with promising associations to treatment response.
Strengthening confidence
The client gained stronger evidence behind the biomarkers' potential, marking a meaningful step toward their precision-medicine goal.
A clearer path forward
Armed with these insights, the client gained a sharper view of targeted patient stratification and subpopulation matching to inform their next steps.
Responder vs Non-Responder Analysis
See the full analytical workflow behind this kind of programme, from defining response through to a testable hypothesis.
Related Case Studies
Solution
Precision Patient Stratification
Case Study
57% Acceleration in MoA Studies
Case Study
Multi-Modal Biomarker Discovery
Like what you see? Let's talk
We listen to your problems, and give you the confidence to make your decision.
Take the first step